Revance Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
NASHVILLE, Tenn. (BUSINESS WIRE) Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings (“Revance” or the “Company”), today announced a proposed underwritten public offering of $150 million of its common stock. In addition, Reva.
Revance Announces Pricing of $200 0 Million Upsized Public Offering of Common Stock streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
PDUFA date of September 8, 2022 for DaxibotulinumtoxinA for Injection in glabellar linesReinspection of manufacturing facility completed as part of Class II BLA resubmission for DaxibotulinumtoxinA for Injection in glabellar linesSecond quarter total revenue of $28.4 million, with RHA® Collection revenue of $25.5 mi.
Conference Call Scheduled for Tuesday, August 9, 2022 at 4:30 p.m. ET.NASHVILLE, Tenn. (BUSINESS WIRE) Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release second quarter 2022 fin.